110 related articles for article (PubMed ID: 10081698)
1. Role of neoadjuvant treatment in clinically confined prostate cancer. Takeda NHT Italian Group.
Prezioso D; Lotti T; Montironi R; Polito M
Eur Urol; 1999; 35 Suppl 1():17-21; discussion 22. PubMed ID: 10081698
[TBL] [Abstract][Full Text] [Related]
2. Leuprorelin 1-month depot as neoadjuvant therapy for prostate cancer. Takeda NHT Italian Group.
Prezioso D; Lotti T; Montironi R; Polito M
Urol Int; 1998; 60 Suppl 2():11-7; discussion 35. PubMed ID: 9607553
[TBL] [Abstract][Full Text] [Related]
3. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
Bullock MJ; Srigley JR; Klotz LH; Goldenberg SL
Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716
[TBL] [Abstract][Full Text] [Related]
4. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
[TBL] [Abstract][Full Text] [Related]
5. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.
Montironi R; Magi-Galluzzi C; Muzzonigro G; Prete E; Polito M; Fabris G
J Clin Pathol; 1994 Oct; 47(10):906-13. PubMed ID: 7525657
[TBL] [Abstract][Full Text] [Related]
6. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
7. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
Gomella LG; Liberman SN; Mulholland SG; Petersen RO; Hyslop T; Corn BW
Urology; 1996 Jun; 47(6):870-7. PubMed ID: 8677579
[TBL] [Abstract][Full Text] [Related]
8. Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study.
Bono AV; Pagano F; Montironi R; Zattoni F; Manganelli A; Selvaggi FP; Comeri G; Fiaccavento G; Guazzieri S; Selli C; Lembo A; Cosciani-Cunico S; Potenzoni D; Muto G; Diamanti L; Santinelli A; Mazzucchelli R; Prayer-Galletti T;
Urology; 2001 Jan; 57(1):117-21. PubMed ID: 11164155
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study.
Prezioso D; Lotti T; Polito M; Montironi R
Urol Int; 2004; 72(3):189-95. PubMed ID: 15084760
[TBL] [Abstract][Full Text] [Related]
10. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
Noguchi M; Noda S; Nakashima O; Kojiro M
Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy.
Pu XY; Wang XH; Wu YL; Wang HP
J Cancer Res Clin Oncol; 2007 Aug; 133(8):555-62. PubMed ID: 17457611
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage C carcinoma of the prostate.
Narayan P; Lowe BA; Carroll PR; Thompson IM
Br J Urol; 1994 May; 73(5):544-8. PubMed ID: 8012777
[TBL] [Abstract][Full Text] [Related]
13. Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group.
Rabbani F; Goldenberg SL; Klotz LH
J Urol; 1998 Mar; 159(3):925-8. PubMed ID: 9474184
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
Debruyne FM; Witjes WP
Mol Urol; 2000; 4(3):251-6;discussion 257. PubMed ID: 11062381
[TBL] [Abstract][Full Text] [Related]
15. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
Matsushima H; Goto T; Hosaka Y; Kitamura T; Kawabe K
Cancer; 1999 Apr; 85(8):1822-7. PubMed ID: 10223578
[TBL] [Abstract][Full Text] [Related]
16. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer.
Selli C; Montironi R; Bono A; Pagano F; Zattoni F; Manganelli A; Selvaggi FP; Comeri G; Fiaccavento G; Guazzieri S; Lembo A; Cosciani-Cunico S; Potenzoni D; Muto G; Mazzucchelli R; Santinelli A;
J Clin Pathol; 2002 Jul; 55(7):508-13. PubMed ID: 12101195
[TBL] [Abstract][Full Text] [Related]
17. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.
Gleave ME; La Bianca SE; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
Urology; 2000 Aug; 56(2):289-94. PubMed ID: 10925096
[TBL] [Abstract][Full Text] [Related]
18. Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers.
Wang X; Qi M; Zhang J; Sun X; Guo H; Pang Y; Zhang Q; Chen X; Zhang R; Liu Z; Liu L; Hao X; Han B
Prostate; 2019 May; 79(7):709-719. PubMed ID: 30825345
[TBL] [Abstract][Full Text] [Related]
19. Significance of the Gleason scoring system after neoadjuvant hormonal therapy.
Bentley G; Dey J; Sakr WA; Wood DP; Pontes JE; Grignon DJ
Mol Urol; 2000; 4(3):125-;discussion 131. PubMed ID: 11062366
[TBL] [Abstract][Full Text] [Related]
20. Laparoscopic radical prostatectomy after neoadjuvant hormonal therapy: an apparently safe and effective procedure.
Brown JA; Garlitz C; Strup SE; Hubosky SG; Gomella L
J Laparoendosc Adv Surg Tech A; 2004 Dec; 14(6):335-8. PubMed ID: 15684777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
